Xeris Biopharma Holdings, Inc. shares rise 2.45% intraday after U.S. Patent and Trademark Office issued patent for Recorlev®.

Xeris Biopharma Holdings, Inc. rose 2.45% in intraday trading, with the company announcing that the U.S. Patent and Trademark Office has issued patent number 12,377,096 for Recorlev® (levoketoconazole). This patent, listed in the 'Orange Book,' covers therapeutic uses of levoketoconazole in methods that minimize drug-drug interactions, which is a positive development for the company.